Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

BACKGROUND: Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies. METHODS: Advanced solid tumor patients received oral MK-2206 45 or 60 mg (QOD) wi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Molife, L Rhoda, Yan, Li, Vitfell-Rasmussen, Joanna, Zernhelt, Adriane M, Sullivan, Daniel M, Cassier, Philippe A, Chen, Eric, Biondo, Andrea, Tetteh, Ernestina, Siu, Lillian L, Patnaik, Amita, Papadopoulos, Kyriakos P, de Bono, Johann S, Tolcher, Anthony W, Minton, Susan
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3884022/
https://ncbi.nlm.nih.gov/pubmed/24387695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-7-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars